FIGURE

Figure 10.

ID

ZDB-FIG-250214-32

Publication

Wawruszak et al., 2025 - Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies

Other Figures

All Figure Page

Back to All Figure Page

Figure 10.

Effect of EX527 or/and PAX on the cell cycle progression in the MCF7 luminal BC cells. (a) BC cells were exposed to individual or concomitant EX527 and PAX treatment for 48 h using selected ratios of the IC₅₀ determined in the MTT assay, stained with propidium iodide (PI) and analysed by FACS. The data are presented as the means ± standard deviation (±SD). (b) CCND1 (cyclin D1) relative gene expression in zebrafish MCF7 injected xenograft model after 72 h with 1/8 IC₅₀ EX527 or/and PAX treatment determined in qPCR method. (c) Representative histograms from the FACS analysis of the MCF7 BC cells after a 48h incubation with EX527 or/and PAX. M1-subG1 (pre-G1) phase; M2-G1 phase; M3-S phase; M4-G2 phase.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J Enzyme Inhib Med Chem